To determine whether PAR2 inhibition by I-287 may have anti-inflammatory effects, we assessed its ability to block the PAR2-mediated release of the inflammatory cytokine interleukin-8 (IL-8) in HCT 116 and human lung carcinoma (A549) cells. Here, F2RL1 is linked to lung carcinoma.